---
title: "百时美施贵宝第三季度营收 122.2 亿美元，预估 118.1 亿美元。第三季度调整后每股收益 1.63 美元。"
description: "百时美施贵宝第三季度营收 122.2 亿美元，预估 118.1 亿美元。第三季度调整后每股收益 1.63 美元。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263496108.md"
published_at: "2025-10-30T11:01:01.000Z"
---

# 百时美施贵宝第三季度营收 122.2 亿美元，预估 118.1 亿美元。第三季度调整后每股收益 1.63 美元。

百时美施贵宝第三季度营收 122.2 亿美元，预估 118.1 亿美元。第三季度调整后每股收益 1.63 美元。

### Related Stocks

- [BMY.US - 百时美施贵宝](https://longbridge.com/zh-CN/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Bristol Myers Squibb Releases Fourth Quarter and Full-Year 2025 Financial Results | Bristol-Myers Squibb Company has released its fourth quarter and full-year 2025 financial results. The earnings press re | [Link](https://longbridge.com/zh-CN/news/274966941.md) |
| Berkshire Asset Management LLC PA Trims Stock Position in Bristol Myers Squibb Company $BMY | Berkshire Asset Management LLC PA reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.6% in Q3, now holdin | [Link](https://longbridge.com/zh-CN/news/276001636.md) |
| Bristol-Myers Squibb Q3 Non-GAAP Earnings Fall, Revenue Rises; Annual Outlook Updated | Bristol-Myers Squibb Q3 Non-GAAP Earnings Fall, Revenue Rises; Annual Outlook Updated | [Link](https://longbridge.com/zh-CN/news/263508417.md) |
| Will the Milvexian Trial Setback Shift Bristol Myers Squibb's (BMY) Cardiovascular Strategy? | Bristol Myers Squibb and Johnson & Johnson discontinued their Phase 3 Librexia ACS trial for milvexian due to unmet effi | [Link](https://longbridge.com/zh-CN/news/266006779.md) |
| Bristol Myers Squibb (BMY): $6.1B One-Off Loss Undermines Recent Profitability Narrative | Bristol-Myers Squibb (BMY) reported a one-off $6.1 billion loss, overshadowing its recent profitability and 7.8% annual  | [Link](https://longbridge.com/zh-CN/news/263692665.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。